Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

IMPORTANCE: Adjuvant imatinib is associated with improved recurrence-free survival (RFS) when administered after surgery to patients with operable gastrointestinal stromal tumor (GIST), but its influence on overall survival (OS) has remained uncertain. OBJECTIVE: To evaluate the effect of adjuvant i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Joensuu, Heikki, Eriksson, Mikael, Sundby Hall, Kirsten, Reichardt, Annette, Hermes, Barbara, Schütte, Jochen, Cameron, Silke, Hohenberger, Peter, Jost, Philipp J., Al-Batran, Salah-Eddin, Lindner, Lars H., Bauer, Sebastian, Wardelmann, Eva, Nilsson, Bengt, Kallio, Raija, Jaakkola, Panu, Junnila, Jouni, Alvegård, Thor, Reichardt, Peter
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2020
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260691/
https://ncbi.nlm.nih.gov/pubmed/32469385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.2091
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items